RT Journal Article
SR Electronic
T1 SARS-CoV-2 Antibody Response is Associated with Age in Convalescent Outpatients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.08.21265888
DO 10.1101/2021.11.08.21265888
A1 Zhai, Bo
A1 Clarke, Karen
A1 Bauer, David L.
A1 Kupul, Saran
A1 Schratz, Lucas J.
A1 Nowalk, M. Patricia
A1 McElroy, Anita K.
A1 McLachlan, James B.
A1 Zimmerman, Richard K.
A1 Alcorn, John F.
YR 2021
UL http://medrxiv.org/content/early/2021/11/08/2021.11.08.21265888.abstract
AB COVID-19 has had an unprecedented global impact on human health. Understanding the antibody memory responses to infection is one tool needed to effectively control the pandemic. Among 173 outpatients who had virologically confirmed SARS-CoV-2 infection, we evaluated serum antibody concentrations, microneutralization activity, and enumerated SARS-CoV-2 specific B cells in convalescent blood specimens. Serum antibody concentrations were variable, allowing for stratification of the cohort into high and low responders. Serum antibody concentration was positively associated with microneutralization activity and participant age, with participants under the age of 30 showing the lowest antibody level. Neither participant sex, the timing of blood sampling following the onset of illness, nor the number of SARS-CoV-2 spike protein specific B cells correlated with serum antibody concentration. These data suggest that young adult outpatients did not generate as robust antibody memory, compared with older adults. Further, serum antibody concentration or neutralizing activity trended but did not significantly correlate with the number of SARS-CoV-2 memory B cells. These findings have direct implications for public health policy and current vaccine efforts. Knowledge gained regarding antibody memory following infection will inform the need for vaccination in those previously infected and allow for a better approximation of population-wide protective immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Centers for Disease Control and Prevention (CDC) 5U01IP001035 and by National Institutes of Health (NIH) UL1TR001857. The Commonwealth of Pennsylvania, Department of Human Services COVID Grant. The DSF Charitable Foundation and the University of Pittsburgh Clinical and Translational Science Institute (CTSI). NIH grant U01 AI124289.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Pittsburgh Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.